The UK National Health Service introduced an MMR vaccine using the Urabe mumps strain in 1988, replacing it entirely with the Jeryl Lynn strain in September 1992 following the identification of an unacceptable risk of aseptic meningitis 15–35 days after vaccination.[29] Decisions taken by British authorities at this time were to be criticized later following documents obtained under the Freedom of Information Act.[30] With no such risk seen in vaccines using the Jeryl Lynn mumps strain,[29][31] the UK NHS withdrew two of the three MMR vaccines then available (Immravax, made by Merieux UK, and Pluserix, made by SmithKline Beecham) in favor of Merck Sharp and Dohme's MMR II brand, based on the Jeryl Lynn strain.[31] Although MMR administration did continue with MMR II, the MMR vaccination rate first began to fall after 1996, following claims by Wakefield that it was linked to the inflammatory bowel disease, Crohn's disease.[32]